Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

A huge student turnout for NBT
2010-02-24

Ms Babongile Bomela (seated, left) and Mr Riekie Vickers (seated, right) with some of the first-year students who wrote the NBT's. They both acted as invigilators for the tests.
Photo: Mangaliso Radebe


More than 5 000 first-year students at the University of the Free State (UFS) recently wrote the National Benchmark Tests (NBT).

These tests are used to complement first-year students’ Grade 12 results and provide a profile of student competencies that the university can use to improve the quality of teaching and learning to enhance student success.

This was the first time that the UFS had made use of the NBTs, which were thoroughly piloted at several South African universities during 2009.

“A total of 5 449 students from the Main, South and Qwaqwa Campuses participated in this very ambitious testing process,” said Ms Merridy Wilson-Strydom from the Centre for Higher Education Studies and Development (CHESD) at the UFS.

“Altogether 7 687 test papers were completed. This is an excellent turn-out and highlights our students’ commitment to their studies.”

It was compulsory for all students (excluding those from the Faculty of Health Sciences) to write the Academic and Quantitative Literacy Test (AQL). Students from the Faculties of Economic and Management Sciences as well as Natural and Agricultural Sciences also wrote the Mathematics Tests.

“AQL targets students’ capacity to engage successfully with the demands of academic study in the medium of instruction, and the ability to manage situations or solve problems in a real context that is relevant to higher education study, using basic qualitative information that may be presented verbally, graphically, in tabular or symbolic form,” she explained.

“The Mathematics Test targets students’ ability with regard to mathematical concepts that are formally regarded as part of the school curriculum and tested in the Mathematics Examination Papers 1 and 2.”

The NBTs have been developed with inputs from over 300 academics from all the 23 universities in the country. They are available in English and Afrikaans.
Data integrity is quality-assured by the Assessment Systems Corporation in Michigan, USA, and further interrogated by the Education Testing Services in Princeton, New Jersey, USA.

The NBT results of UFS students will be available by the middle of March 2010. First-year students who do not perform at the required proficiency level in the academic literacy domain will be required to complete a language development module. This module is offered in both English and Afrikaans, depending on the chosen medium of instruction of the student.

Media Release:
Mangaliso Radebe
Assistant Director: Media Liaison
Tel: 051 401 2828
Cell: 078 460 3320
E-mail: radebemt@ufs.ac.za  
2 March 2010
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept